Medicure (MCUJF) EBITDA (2009 - 2026)

Medicure's EBITDA history runs 18 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, EBITDA rose 354.63% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a 154.8% increase from a year earlier, with the FY2025 full-year figure at -$4.9 million, down 146.61% from the prior year.
• EBITDA improved to $1.2 million in Q1 2026 per MCUJF's latest filing, from $55215.6 in the prior quarter.
• Across five years, EBITDA topped out at $4.0 million in Q4 2022 and bottomed at -$848142.8 in Q3 2024.
• The 5-year median for EBITDA is $67879.7 (2023), against an average of $573609.4.
• Across the five-year window, EBITDA surged 452.69% in 2023 and slumped 1718.71% in 2025, its largest moves.
• Year by year, EBITDA stood at $4.0 million in 2022, then slumped by 92.69% to $291610.6 in 2023, then sank by 222.74% to -$357924.6 in 2024, then surged by 115.43% to $55215.6 in 2025, then surged by 2005.12% to $1.2 million in 2026.
• Per Business Quant, the three latest MCUJF EBITDA figures stand at $1.2 million (Q1 2026), $55215.6 (Q4 2025), and $645978.5 (Q3 2025).